Literature DB >> 12432825

Genetic diseases of muscle.

Kathryn R Wagner1.   

Abstract

In the last twenty years, the genetic basis for most of the inherited myopathies and muscular dystrophies has been unveiled. Diseases have been found to result from loss of function of structural components of the muscle basal lamina (e.g., MCD1A), sarcolemma (e.g., the sarcoglycanopathies), nucleus (e.g., EDMD) and sarcomere (e.g., the nemaline myopathies). A few have been associated with abnormalities in the genes for muscle enzymes (e.g., calpain and fukutin). Alternate mechanisms of pathogenesis have also recently been suggested by mutations lying outside of coding regions, such as the "field effect" of chromosomal mutations in DM2. In the future, we will likely identify the genes responsible for the remaining disorders, including many of the distal myopathies. In addition, we may also find skeletal muscle diseases associated with some of the presently non-implicated muscle proteins: syntropin, dystrobrevin, epsilon-sarcoglycan and sarcospan. The next steps may be to identify and understand the relationship of modifier genes producing the phenotypic heterogeneity of many of these diseases and to characterize those and other targets for therapeutic intervention, whether by gene therapy or by pharmacological treatment.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12432825     DOI: 10.1016/s0733-8619(02)00002-6

Source DB:  PubMed          Journal:  Neurol Clin        ISSN: 0733-8619            Impact factor:   3.806


  13 in total

1.  Determination of miRNA targets in skeletal muscle cells.

Authors:  Zhan-Peng Huang; Ramón Espinoza-Lewis; Da-Zhi Wang
Journal:  Methods Mol Biol       Date:  2012

2.  Application of microRNA in cardiac and skeletal muscle disease gene therapy.

Authors:  Zhan-Peng Huang; Ronald L Neppl; Da-Zhi Wang
Journal:  Methods Mol Biol       Date:  2011

Review 3.  The muscular dystrophies: from genes to therapies.

Authors:  Richard M Lovering; Neil C Porter; Robert J Bloch
Journal:  Phys Ther       Date:  2005-12

4.  Altered nuclear dynamics in MDX myofibers.

Authors:  Shama R Iyer; Sameer B Shah; Ana P Valencia; Martin F Schneider; Erick O Hernández-Ochoa; Joseph P Stains; Silvia S Blemker; Richard M Lovering
Journal:  J Appl Physiol (1985)       Date:  2016-12-15

5.  Restoration of gamma-sarcoglycan localization and mechanical signal transduction are independent in murine skeletal muscle.

Authors:  Elisabeth R Barton
Journal:  J Biol Chem       Date:  2010-04-06       Impact factor: 5.157

6.  Malformed mdx myofibers have normal cytoskeletal architecture yet altered EC coupling and stress-induced Ca2+ signaling.

Authors:  Richard M Lovering; Luke Michaelson; Christopher W Ward
Journal:  Am J Physiol Cell Physiol       Date:  2009-07-15       Impact factor: 4.249

Review 7.  Eccentric exercise in aging and diseased skeletal muscle: good or bad?

Authors:  Richard M Lovering; Susan V Brooks
Journal:  J Appl Physiol (1985)       Date:  2013-03-07

8.  Effects of in vivo injury on the neuromuscular junction in healthy and dystrophic muscles.

Authors:  Stephen J P Pratt; Sameer B Shah; Christopher W Ward; Mario P Inacio; Joseph P Stains; Richard M Lovering
Journal:  J Physiol       Date:  2012-10-29       Impact factor: 5.182

9.  Superparamagnetic Iron Oxide Nanoparticles in Musculoskeletal Biology.

Authors:  Shama R Iyer; Su Xu; Joseph P Stains; Craig H Bennett; Richard M Lovering
Journal:  Tissue Eng Part B Rev       Date:  2017-01-11       Impact factor: 7.376

10.  Disruption of action potential and calcium signaling properties in malformed myofibers from dystrophin-deficient mice.

Authors:  Erick O Hernández-Ochoa; Stephen J P Pratt; Karla P Garcia-Pelagio; Martin F Schneider; Richard M Lovering
Journal:  Physiol Rep       Date:  2015-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.